Comparing Abrdn Japan Equity Fund (NYSE:JEQ) & VanEck Biotech ETF (NASDAQ:BBH)

VanEck Biotech ETF (NASDAQ:BBH) and Abrdn Japan Equity Fund (NYSE:JEQ) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Volatility & Risk

VanEck Biotech ETF has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Abrdn Japan Equity Fund has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Dividends

VanEck Biotech ETF pays an annual dividend of $1.25 per share and has a dividend yield of 0.8%. Abrdn Japan Equity Fund pays an annual dividend of $0.36 per share and has a dividend yield of 6.2%.

Earnings and Valuation

This table compares VanEck Biotech ETF and Abrdn Japan Equity Fund”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VanEck Biotech ETF	N/A	N/A	N/A	N/A	N/A
Abrdn Japan Equity Fund	$19.55 million	4.14	N/A	N/A	N/A

Profitability

This table compares VanEck Biotech ETF and Abrdn Japan Equity Fund’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VanEck Biotech ETF	N/A	N/A	N/A
Abrdn Japan Equity Fund	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for VanEck Biotech ETF and Abrdn Japan Equity Fund, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VanEck Biotech ETF	0	5	3	0	2.67
Abrdn Japan Equity Fund	0	0	0	0	0.00

VanEck Biotech ETF presently has a consensus price target of $162.53, suggesting a potential upside of 0.00%. Given VanEck Biotech ETF’s stronger consensus rating and higher probable upside, research analysts clearly believe VanEck Biotech ETF is more favorable than Abrdn Japan Equity Fund.

Institutional & Insider Ownership

32.0% of VanEck Biotech ETF shares are held by institutional investors. Comparatively, 62.7% of Abrdn Japan Equity Fund shares are held by institutional investors. 52.1% of Abrdn Japan Equity Fund shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Abrdn Japan Equity Fund beats VanEck Biotech ETF on 5 of the 8 factors compared between the two stocks.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

About Abrdn Japan Equity Fund

Abrdn Japan Equity Fund Inc is a close ended equity mutual fund launched and managed by Aberdeen Standard Investments (Asia) Limited. It invests in the public equity markets of Japan. The fund invests in stocks of companies operating across diversified sectors. It employs quantitative analysis to build its portfolio. The fund employs a quantitative analysis to create its portfolio. It benchmarks the performance of its portfolio against the TOPIX Index. The fund was previously known as Japan Equity Fund, Inc. Abrdn Japan Equity Fund Inc was formed on July 12, 1990 and is domiciled in the United States.